Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 10/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 4/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30664346 | 1.00 | METAP2 (0.47) | METAP2ROCK2DYRK1ANFATC1GSK3B | |
| SCHEMBL20122894 | 0.94 | METAP2 (0.41) | METAP2ROCK2DYRK1ANFATC1GSK3B | |
| SCHEMBL30664163 | 0.94 | METAP2 (0.41) | METAP2ROCK2DYRK1ANFATC1GSK3B | |
| SCHEMBL30664343 | 0.93 | ROCK2 (0.45) | METAP2ROCK2DYRK1AKCNH2 | |
| SCHEMBL20122763 | 0.93 | ROCK2 (0.45) | METAP2ROCK2DYRK1AKCNH2 | |
| SCHEMBL30664250 | 0.91 | ROCK2 (0.41) | METAP2ROCK2 | |
| SCHEMBL20122999 | 0.91 | ROCK2 (0.41) | METAP2ROCK2 | |
| SCHEMBL30664257 | 0.90 | ROCK2 (0.44) | METAP2ROCK2KCNH2 | |
| SCHEMBL20122760 | 0.90 | ROCK2 (0.44) | METAP2ROCK2KCNH2 | |
| SCHEMBL30664283 | 0.89 | METAP2 (0.39) | METAP2ROCK2DYRK1ANFATC1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2021-09-28 | — | — | US | disclosed |
| EP-3792262-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2021-03-17 | — | — | EP | disclosed |
| EP-3535263-B1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2020-09-30 | — | — | EP | disclosed |
| EP-3318563-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2018-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | METAP2 3515/4885ROCK2 1093/4885DYRK1A 493/4885 |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | METAP2 3515/4885ROCK2 1093/4885DYRK1A 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.